A simple blood test may be able to tell apparently healthy older adults whether they face a high risk of developing Alzheimer's disease within the next decade, a finding that could reshape how researchers recruit for drug trials and, eventually, how families plan for the future.
The test measures a protein called p-tau217, a form of tau that correlates with the amyloid plaque buildup long associated with Alzheimer's. Researchers at the Mass General Brigham Neuroscience Institute found that symptom-free older adults with very high levels of p-tau217 faced a 38 percent risk of developing cognitive impairment within five years. Over ten years, that risk climbed to 78 percent.
The findings, published in JAMA and presented at the Alzheimer's Association International Conference in London, drew immediate interest, and immediate caution, from the Alzheimer's research community. The study analyzed data from 2,684 older adults enrolled in long-running Alzheimer's studies, with yearly cognitive checkups stretching back to 2004. Of that group, roughly 478 developed cognitive impairment over the tracking period.
Dr. Reisa Sperling, the study's senior author and a researcher at Mass General Brigham, framed the blood marker as a gauge of disease progression rather than a binary diagnosis.
"This is a gradual process where amyloid and tau build up in the brain and this blood-based biomarker is telling you how far you are in that process."
Only the very highest p-tau217 readings appeared to correlate with what researchers described as a "tipping point", the stage at which amyloid accumulation begins triggering the formation of tau tangles, a hallmark of advancing Alzheimer's pathology. Participants with very low p-tau217 levels showed a low risk of impairment over the same five- to ten-year window.
But the ten-year estimate carries a built-in asterisk. Only a small fraction of the study's participants had been tracked for a full decade, which means the longer-range projection rests on thinner data. That gap matters for anyone tempted to treat the numbers as a personal prognosis.
Drs. Suzanne Schindler of Washington University in St. Louis and David Wolk of the University of Pennsylvania, who co-authored a commentary in JAMA alongside the study, acknowledged the work had "provided a crucial piece of the puzzle." But they added a pointed qualifier: the blood tests "are not yet precise enough to guide individualized prognosis." Their commentary noted that older adults may face competing health risks, heart-related problems that cause vascular dementia, or the simple reality of dying from something else entirely, factors that could cloud any predictive model.
The p-tau217 test already exists in clinical settings, where it helps doctors evaluate patients who are already showing signs of cognitive trouble. The new study asks a different question: Can the same blood draw tell a healthy person what lies ahead?
For now, the researchers' answer is a firm "not yet."
Sperling was direct about the limits of acting on the information today:
"At this point, it wouldn't change what I would tell someone to do. I'd still tell them to eat well, sleep well, exercise a lot and stay engaged."
Her advice to the public was blunt: "Wait and get tested when you can potentially do something about it."
That "something" remains the missing piece. No approved drug currently prevents Alzheimer's in people who have not yet developed symptoms. Large clinical trials are underway testing whether early intervention can slow or stop the disease before it manifests, but those trials have not yet produced results that would give a positive blood test an actionable follow-up.
Jessica Langbaum of the Banner Alzheimer's Institute in Phoenix said the demand is already outpacing the science. She described people approaching her and saying, "I want this blood test. I have a family history of Alzheimer's disease." Yet Langbaum herself strongly discourages healthy individuals from seeking the test at this stage. She called the study's findings "quite strong" but said a predictive blood test would be "really important" only if ongoing studies eventually find a drug that could help people before symptoms begin.
The immediate practical value may lie not in doctor's offices but in research enrollment. One of the most persistent bottlenecks in Alzheimer's drug development is finding the right participants, people who are on the path toward the disease but haven't yet crossed the threshold into symptoms. Brain scans and spinal-fluid tests can identify such candidates, but those procedures are expensive, invasive, and difficult to scale.
A blood test changes that calculus. Fox News reported on a related Washington University study finding that p-tau217 levels rise in a "remarkably consistent" pattern long before memory loss begins, effectively acting as a biological clock. That study found the test could estimate when symptoms would appear with a margin of error of three to four years. People who first showed abnormal p-tau217 levels around age 60 didn't develop symptoms for roughly 20 years; those with abnormal levels at 80 developed symptoms after about 10 years.
Rebecca M. Edelmayer, Ph.D., of the Alzheimer's Association, noted that "a blood test is generally much less expensive and easier to administer than a brain scan or spinal-fluid test," adding that it could eventually help doctors and researchers identify people who may benefit from early treatments.
If researchers can use p-tau217 levels to screen large populations quickly and cheaply, they can fill clinical trials faster with the patients most likely to benefit, and most likely to show measurable results. That could shave years off the development timeline for preventive therapies. For the millions of American families watching a parent or grandparent slip away, years matter.
More than six million Americans live with Alzheimer's disease, and that number is projected to grow as the population ages. The financial burden is staggering: the Alzheimer's Association has previously estimated annual costs in the hundreds of billions, borne by families, insurers, and taxpayers through Medicare and Medicaid. Every year without an effective preventive treatment deepens that toll.
AP News confirmed the core findings: the p-tau217 test is promising for trial recruitment but not yet ready for routine use in healthy individuals. The New York Post likewise reported that the test is currently used to help diagnose cognitive problems but is not recommended for symptom-free people seeking predictive information. Breitbart's coverage echoed the same caution: experts stress the test is most valuable right now for identifying high-risk participants for clinical drug trials, not for individual prognosis.
That consensus, promising science, premature application, is worth taking seriously. The history of medicine is littered with screening tools that generated anxiety without offering solutions. A test that tells a healthy 70-year-old she has a 78 percent chance of cognitive impairment within a decade, but offers no approved treatment to change that trajectory, creates a burden without a remedy. The researchers themselves recognize this, which is why their public message is cautious even as their data is striking.
The open questions are significant. The study does not specify what p-tau217 thresholds define "very high" or "very low" in precise clinical terms. It does not name the specific drugs under investigation in the large prevention trials that could eventually give the test practical meaning. And the ten-year risk estimate, while headline-grabbing, rests on a limited subset of participants who were followed that long.
None of that diminishes what the research accomplished. Identifying who is most likely to develop Alzheimer's, years before the first forgotten name or missed turn, is a prerequisite for any serious prevention strategy. The science is moving. The question is whether the drug pipeline can keep pace.
For families who have watched Alzheimer's hollow out the people they love, a blood test that works is not an abstraction. It is the difference between helpless waiting and informed action, once medicine gives them something to act on.
